• Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration
• Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development
NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.
Sandwich, Kent, November 4 2020 - Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to welcome contract research organisation Transpharmation Ltd as a new tenant.
Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.
• Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with
enhanced therapeutic index
• Development to focus on targets associated with haematological and solid tumours
NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.
Enesi Pharma is delighted to announce the appointment of Dr Keith Howard as Chief Scientific Officer. Dr Howard is a seasoned vaccine development expert who will lead Enesi’s R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.